Research programme: platelet-derived growth factor receptor antagonists - Pulmokine

Drug Profile

Research programme: platelet-derived growth factor receptor antagonists - Pulmokine

Alternative Names: PDGF receptor kinase inhibitors - Pulmokine; PK 10571

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator YM BioSciences
  • Developer Pulmokine
  • Class Small molecules
  • Mechanism of Action Platelet-derived growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Pulmonary arterial hypertension

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in USA (Inhalation)
  • 27 Mar 2014 Pulmokine receives Stage B Vascular Interventions and Therapeutic Advances (VITA) contract from National Heart, Lung and Blood Institute in the USA for inhaled PDGFR antagonists development in Pulmonary arterial hypertension
  • 14 Jan 2014 Pulmokine receives phase II SBIR grant from National Institutes of Health USA for PDGFR antagonist development in Pulmonary arterial hypertension (**ADMN)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top